We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficient model-based bioequivalence testing.
- Authors
Möllenhoff, Kathrin; Loingeville, Florence; Bertrand, Julie; Nguyen, Thu Thuy; Sharan, Satish; Zhao, Liang; Fang, Lanyan; Sun, Guoying; Grosser, Stella; Mentré, France; Dette, Holger
- Abstract
The classical approach to analyze pharmacokinetic (PK) data in bioequivalence studies aiming to compare two different formulations is to perform noncompartmental analysis (NCA) followed by two one-sided tests (TOST). In this regard, the PK parameters area under the curve (AUC) and $C_{\max}$ are obtained for both treatment groups and their geometric mean ratios are considered. According to current guidelines by the U.S. Food and Drug Administration and the European Medicines Agency, the formulations are declared to be sufficiently similar if the $90\%$ confidence interval for these ratios falls between $0.8$ and $1.25 $. As NCA is not a reliable approach in case of sparse designs, a model-based alternative has already been proposed for the estimation of $\rm AUC$ and $C_{\max}$ using nonlinear mixed effects models. Here we propose another, more powerful test than the TOST and demonstrate its superiority through a simulation study both for NCA and model-based approaches. For products with high variability on PK parameters, this method appears to have closer type I errors to the conventionally accepted significance level of $0.05$, suggesting its potential use in situations where conventional bioequivalence analysis is not applicable.
- Subjects
EUROPEAN Medicines Agency; UNITED States. Food &; Drug Administration; FALSE positive error; CONFIDENCE intervals; PHARMACOKINETICS; COMPUTER simulation; RESEARCH; CHAOS theory; RESEARCH methodology; EVALUATION research; COMPARATIVE studies; CROSSOVER trials
- Publication
Biostatistics, 2022, Vol 23, Issue 1, p314
- ISSN
1465-4644
- Publication type
journal article
- DOI
10.1093/biostatistics/kxaa026